Respiratory Interleukin-5 Inhibitor
Customize your policy alerts
Sign up for UnitedHealthcare Policy 2026D0055AA alerts
Get alerted when Policy 2026D0055AA changes without checking for updates manually.
Monitor payer policy activity
This policy governs UnitedHealthcare Commercial and Individual Exchange coverage and prior authorization for provider-administered Cinqair, Exdensur, Fasenra, and Nucala used for eosinophilic granulomatosis with polyangiitis or severe eosinophilic asthma. It also specifies benefit routing, authorization duration, prescriber requirements, combination-therapy exclusions, and continuation criteria.
Exdensur (depemokimab-ulaa) was added to the applicable provider-administered drug products for subcutaneous administration.
Exdensur was designated proven and medically necessary for add-on maintenance treatment of severe asthma with an eosinophilic phenotype when the policy criteria are met.
Fasenra administered by a provider was designated proven and medically necessary for hypereosinophilic syndrome lasting at least 6 months without an identifiable non-hematologic secondary cause when the policy criteria are met.
Nucala coverage for provider-administered COPD was revised to require inadequately controlled COPD with an eosinophilic phenotype.
The policy updated the list of anti-interleukin-5 therapies that must not be used in combination with Cinqair, Fasenra, Nucala, or Exdensur.
The Cinqair eosinophilic-phenotype criterion was revised to use a baseline pre-treatment peripheral-blood eosinophil level of at least 150 cells per microliter.
Combination-therapy requirements were removed for Nucala coverage for chronic rhinosinusitis with nasal polyps and COPD.
The policy revised the chronic rhinosinusitis with nasal polyps criterion to require Nucala as add-on maintenance therapy and an inadequate response to nasal corticosteroids.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.